Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

Company Overview

Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized cancer immunotherapies. Its lead platform uses a patient’s own dendritic cells, which are immune cells collected from the patient and prepared to recognize and stimulate an immune response against tumor tissue.

The company’s principal investigational product is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational treatment intended for injection directly into inoperable solid tumors. These products remain investigational and are not broadly approved cancer treatments.

Northwest Biotherapeutics has conducted clinical development activities in the United States and Europe, including the United Kingdom and Germany. The company has worked with manufacturing and clinical partners in the United Kingdom, where its personalized vaccine manufacturing operations have been based. Linda Powers has served as the company’s chief executive officer and chairwoman.

Key Stats

• Today's Range: $0.16 to $0.16
• 50-Day Range: $0.16 to $0.19
• 52-Week Range: $0.14 to $0.34
• Volume: 2.35 million shs
• Average Volume: 3.39 million shs
• Market Capitalization: $277.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Northwest Biotherapeutics Stock Analysis - MarketRank™

Northwest Biotherapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Northwest Biotherapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.46% of the float of Northwest Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Northwest Biotherapeutics has a short interest ratio ("days to cover") of 19.76, which indicates bearish sentiment.

Change versus previous month

Short interest in Northwest Biotherapeutics has recently increased by 7.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Northwest Biotherapeutics does not currently pay a dividend.

Dividend Growth

Northwest Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Northwest Biotherapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for NWBO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.40% of the stock of Northwest Biotherapeutics is held by insiders.

Percentage Held by Institutions

0.04% of the stock of Northwest Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NWBO
• Previous Symbol: NASDAQ:NWBO
• CIK: 1072379
• Web: www.nwbio.com
• Phone: (240) 497-9024
• Fax: 240-627-4121
• Employees: 20
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($18.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.16 million
• Net Margins: -1,736.35%
• Pretax Margin: -1,761.07%
• Return on Equity: N/A
• Return on Assets: -56.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: $1.38 million
• Price / Sales: 201.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -4.00

Miscellaneous

• Outstanding Shares: 1,734,405,000
• Free Float: 1,692,779,000
• Market Cap: $277.50 million
• Optionable: Not Optionable
• Beta: -0.61